“It is easy to stay committed to client timelines and project quality when there is no turnover and controlled organic growth,” Daviau said. “Because we offer benefits and a nurturing environment that rewards commitment to quality and innovation, we find ourselves in a position to bring more outstanding candidates into the fold.”
Unlike other CROs replacing headcount from attrition or layoffs, CoreRx has not lost a single employee in their existence. The company has not been a part of the large-scale layoffs which have dominated the pharmaceutical industry in recent months, and that put CoreRx in a better position as the recovery takes root.
Keep on top of new developments and throughout the drug development industry by following us on Twitter: www.twitter.com/CoreRx.